Biotech · Private company
NeoImmuneTech
Track this companyFree. Adds NeoImmuneTech to your Dealase workspace and tells you when its record changes.
Clinical trials134 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- atezolizumabPhase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- efineptakin alfaPhase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- NT-I7Phase 2 · Any Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- NT-I7Phase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumab (KEYTRUDA®)Phase 2 · Any Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Axicabtagene ciloleucelPhase 1 · Refractory Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Double-Blind NT-I7Phase 1 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- Efineptakin alfaPhase 1 · Refractory Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Lisocabtagene MaraleucelPhase 1 · Refractory Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 1 · Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)ClinicalTrials.gov · fetched Nov 12, 2026
- NT-I7Phase 1 · Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)ClinicalTrials.gov · fetched Nov 12, 2026
- TisagenlecleucelPhase 1 · Refractory Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)PHASE1 · RECRUITING · started Jun 5, 2026ClinicalTrials.gov NCT07200089 · fetched Nov 12, 2026
- NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell LymphomaPHASE1 · RECRUITING · started Mar 12, 2026ClinicalTrials.gov NCT07052305 · fetched Nov 12, 2026
- Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent GlioblastomaPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 24, 2023ClinicalTrials.gov NCT05465954 · fetched Nov 12, 2026
- NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLCPHASE2 · TERMINATED · started Nov 15, 2021ClinicalTrials.gov NCT04984811 · fetched Nov 12, 2026
- Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyPHASE1 · COMPLETED · started Jul 29, 2021ClinicalTrials.gov NCT05075603 · fetched Nov 12, 2026
- NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing SurgeryPHASE1 · TERMINATED · started Mar 12, 2021ClinicalTrials.gov NCT04588038 · fetched Nov 12, 2026
- NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal AdenocarcinomaPHASE1 · TERMINATED · started Jan 21, 2021ClinicalTrials.gov NCT04594811 · fetched Nov 12, 2026
- A Trial of NT-I7 in COVID-19 (SPESELPIS)PHASE1 · TERMINATED · started Nov 27, 2020ClinicalTrials.gov NCT04501796 · fetched Nov 12, 2026
- NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid TumorsPHASE1_PHASE2 · COMPLETED · started Jun 10, 2020ClinicalTrials.gov NCT04332653 · fetched Nov 12, 2026
- High-Risk Skin Cancers With Atezolizumab Plus NT-I7PHASE1_PHASE2 · TERMINATED · started Dec 26, 2019ClinicalTrials.gov NCT03901573 · fetched Nov 12, 2026
- rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and TemozolomidePHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 4, 2019ClinicalTrials.gov NCT03687957 · fetched Nov 12, 2026
- Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade GliomasPHASE1 · TERMINATED · started Oct 30, 2018ClinicalTrials.gov NCT02659800 · fetched Nov 12, 2026
- Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor ActivityPHASE2 · TERMINATED · started Jul 7, 2014ClinicalTrials.gov NCT02124902 · fetched Nov 12, 2026